In five cohorts including melanoma, this doublet (N-803 combined with anti-PD-1/PD-L1) is combined with an NK-based cellular therapy (termed PD-L1 t-haNK), with those patients progressing on the doublet therapy able to transfer to the triplet therapy. The gene discussed is CD274; the disease is melanoma.